Physicians Signal High Likelihood to Prescribe Moleculin's Annamycin for Relapsed/Refractory AML — Moleculin Biotech, Inc.

Event summary

6 of 7 surveyed oncologists reported high likelihood to prescribe Annamycin for relapsed/refractory AML.
Physicians cited deep remissions, transplant-bridging potential, biomarker-agnostic use, and reduced cardiotoxicity as key drivers.
Payers expressed strong support for Annamycin filling a significant unmet need in R/R AML.
Moleculin's MIRACLE Trial (MB-108) is ongoing, following a successful Phase 1B/2 study (MB-106).

The big picture

The strong physician intent to prescribe Annamycin underscores the significant unmet need in relapsed/refractory AML, particularly for patients without actionable mutations or those who fail venetoclax-based therapy. The biomarker-agnostic applicability and reduced cardiotoxicity of Annamycin position it as a potential differentiator in a treatment landscape dominated by targeted therapies. The ongoing MIRACLE Trial will be critical in validating these early signals of clinical and commercial potential.

What we're watching

Clinical Validation: Whether Annamycin's reported efficacy and safety profile will be confirmed in ongoing and future clinical trials.
Regulatory Pathway: The pace at which Moleculin advances Annamycin through the MIRACLE Trial and secures potential FDA approval.
Commercial Adoption: How physician and payer enthusiasm translates into real-world prescribing patterns and market uptake.